Table 4.
Overall costs in first year | All sample | Men | Women | Mann–Whitney test |
---|---|---|---|---|
Total overall costs | 5,944.1 (2,656.4) | 6,888.2 (2,881.5) | 4,879.0 (2,441.5) | 0.002 |
Hospital stays | 3,116.4 (1,729.7) | 3,424.4 (1,729.7) | 2,769.0 (1,729.7) | 0.017 |
Outpatient services | 1,051.2 (597.4) | 1,106.5 (609.8) | 988.8 (576.9) | 0.251 |
Direct-distribution pharmaceuticals | 1,083.8 (0) | 1,388.1 (0) | 740.6 (0) | 0.083 |
Other pharmaceuticals | 243.2 (91.1) | 294.2 (120.9) | 185.7 (61.0) | <0.001 |
Emergency room | 50.2 (0) | 53.5 (0) | 46.6 (0) | 0.294 |
Hospice stays | 5.2 (0) | 9.9 (0) | 0.0 (0) | 0.035 |
Medical devices | 394.0 (0) | 611.7 (0) | 148.4 (0) | 0.369 |
Melanoma-specific costs in first year | All sample | Men | Women | Mann–Whitney test |
---|---|---|---|---|
Total melanoma-specific costs | 3,942.5 (2,110.7) | 4,487.5 (2,157.5) | 3,327.8 (2,057.3) | 0.035 |
Hospital stays | 2,135.7 (1,729.7) | 2,298.5 (1,729.7) | 1,952.0 (1,729.7) | 0.109 |
Outpatient services | 901.5 (500.9) | 949.2 (501.1) | 847.7 (498.6) | 0.622 |
Direct-distribution pharmaceuticals | 897.5 (0) | 1,228.0 (0) | 524.6 (0) | 0.244 |
Other pharmaceuticals | 3.1 (0) | 3.4 (0) | 2.9 (0) | 0.591 |
Emergency room | 0.8 (0) | 1.0 (0) | 0.6 (0) | 0.853 |
Hospice stays | 3.9 (0) | 7.4 (0) | 0.0 (0) | 0.060 |